Interaction of iPSC-derived MSCs with the gastrointestinal tract and microbiome in the management of inflammatory bowel disease

Lyndah Chow,Alison Manchester,Steven Dow
DOI: https://doi.org/10.1016/b978-0-323-85545-7.00009-0
2022-01-01
Abstract:Cellular therapy has undergone many advances in the past decade with the advent of new technology, including the development of pluripotent stem cells from tissue sources other than the embryo. Using induced pluripotent stem cells (iPSC) and their differentiated progeny promises a stable and unlimited source of cells that can be used to combat disease and study rare conditions in a laboratory environment. Particularly the use of iPSC-derived mesenchymal stem cells (iMSC), which have the potential to be used to moderate various immune associated or inflammatory conditions such as inflammatory bowel disease This review explores the current understanding of mechanisms involved in how primary tissue–derived MSC and iPSC-derived MSC are able to modulate the inflammatory response and promote intestinal healing when used as a cellular therapy; the utility of using iMSC in clinical trials, and discusses the reasoning behind the lack of iMSC use compared to primary MSC. Lastly, this review also delves into the influence of the gut microbiome on gastrointestinal tract diseases, and showcases how cellular therapy is able to effect positive changes in the bacterial composition leading to resolution of disease pathology.
What problem does this paper attempt to address?